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Aims In patients with atrial fibrillation (AF) pharmacological or electrical cardioversion may be performed to restore
sinus rhythm. The procedure is associated with an increased risk of thromboembolic events, which can be signifi-
cantly reduced by adequate anticoagulation (OAC). Our aim was to create a partly prospective, partly retrospec-
tive cardioversion registry, particularly focusing on OAC strategies in different European countries, and on emerg-
ing choice of OAC over time.
...................................................................................................................................................................................................
Methods From September 2014 to October 2015, cardioversions due to AF performed in six European city hospitals in five
European countries (Hungary: Budapest-1 and -2; Italy: Bari and Pisa; France: Amiens; Spain: Madrid; and Lithuania:
Kaunas) were recorded in the registry.
...................................................................................................................................................................................................
Results A total of 1101 patients (retrospective/prospective: 679/422, male/female: 742/359, mean age: 67.3 years ± 11.2) were
registered. Most of the cardioversions were electrical (97%). Oral anticoagulants were administered in 87% of the
patient, the usage of non-VKA oral anticoagulants (NOACs) vs Vitamin K antagonists (VKA) was 31.5% vs 68.5%, respec-
tively. Seventy seven percent of the patients were given oral anticoagulants more than 3 weeks prior to the procedure,
and 86% more than 4 weeks after the procedure. When using VKA, international normalized ratio (INR) at cardiover-
sion was above 2.0 in 76% of the cases. A decline in VKA usage (P= 0.033) in elective cardioversion over approximately
1 year was observed. During the observation period, there was an increase in apixaban (P< 0.001), a slight increase in
rivaroxaban (P= 0.028) and no changes in dabigatran (P= 0.34) usage for elective cardioversion. There were differences
in use of OAC between the countries: Spain used most VKA (89%), while France used least VKA (39%, P< 0.001).
...................................................................................................................................................................................................
Conclusion According to current AF guidelines, NOACs are adequate alternatives to VKA for thromboembolic prevention in
AF patients undergoing elective cardioversion. Our results indicate that NOAC use is increasing and there is a sig-
nificant decrease in VKA use.
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Atrial fibrillation or flutter (AF) is the most common type of sustained
cardiac arrhythmia. To restore sinus rhythm one option is to perform
a cardioversion. There are two types of cardioversions: pharmaco-
logical and electrical. The procedure is associated with a risk of
thromboembolic events, most commonly ischaemic stroke.1
Adequate anticoagulation can significantly reduce the incidence of
thromboembolic complications. According to current AF guidelines
(ESC 20162 and AHA/ACC 20143) adequate oral anticoagulation
(OAC) is recommended for at least 3 weeks prior to and for 4 weeks
after cardioversion in patients with AF of >_ 48 h or unknown dura-
tion. As an alternative to OAC, transoesophageal echocardiography
can be performed before cardioversion to rule out left atrial
thrombus.
Vitamin K antagonists (VKA) can prevent thromboembolic epi-
sodes during cardioversion.4 A great amount of clinical experience is
available on VKA,5 but there are some limitations to their usage, such
as the requirement of continuous laboratory monitoring and the
numerous drug and food interactions. Since the advent of non-VKA
oral anticoagulants (NOACs) there are now several alternatives used
for prevention of stroke in patients with AF.6–12 The NOACs
comprize dabigatran, a direct thrombin inhibitor, and rivaroxaban,
apixaban and edoxaban, which are direct Xa factor antagonists.
With regards to cardioversion, X-VERT was the first prospective
randomized trial to show that rivaroxaban can prevent thromboem-
bolic complications as effectively as VKA in patients undergoing cardi-
oversion.13 Also the recently published ENSURE-AF14 trial and the
post hoc analyses of the RE-LY15 and ARISTOTLE16 trials proved that
edoxaban, dabigatran, and apixaban can be safely used as well. In addi-
tion, several single-centre trials and meta-analyses confirmed the low
number of thromboembolic events and safe use of NOACs during
cardioversion.17-20
Aims
Our aim was to create a partly prospective and partly retrospective
cardioversion registry, particularly focusing on OAC strategies in dif-
ferent European countries (Hungary, Italy, France, Spain, Lithuania),
and on emerging choices over time for anticoagulants in this setting.
Methods
Design and patients
All patients in the study centres who underwent electrical or pharmaco-
logical cardioversion of AF or flutter were included in the registry. Patient
records were collected in seven cardiology departments of six different
European cities in five European countries, namely (i) Budapest—
Hungary, (ii) Budapest—Hungary, (iii) Pisa—Italy, (iv) Bari—Italy, (v)
Madrid—Spain, (vi) Amiens—France, and (vii) Kaunas—Lithuania.
Data were recorded between September 2014 and October 2015, in
the 7 months prior to start date of the registry, and in the 6 months fol-
lowing the start date of the registry. The retrospective and prospective
design was chosen in order to align the timing to the 12 months following
the presentation of the X-VERT trial, in order to assess whether its publi-
cation would influence NOAC uptake in the cardioversion setting.
Data collection was performed in in-patient and out-patient cardiology
departments. All cardioversions during electrophysiological procedures
were excluded; also data from emergency departments were not col-
lected. Cardioversions were performed according to local protocols. The
study was approved by the ethics committee in participating centres/coun-
try. For all patients a case report form was completed, and subsequently
databased. Cardiovascular endpoints were not assessed in this registry.
Statistical methods
We used the Pearson chi-squared test to compare NOAC vs. VKA in de
novo prescriptions prior to scheduled cardioversion (yes/no), duration of
OAC before cardioversion (more/less than 3 weeks), and duration of
OAC after cardioversion (more/less than 4 weeks). The Pearson chi-
squared test was also used to compare Spain and France in use of anticoa-
gulants (yes/no). To analyse changes in OAC usage over time, we used
logistic regression with OAC (yes/no) as the outcome variable and the
number of months since 1 January 2014 as explanatory variable. The plots
of OAC usage over time were smoothed with 1-nearest-neighbour and
2-nearest-neighbour averaging. Stata 14 (StataCorp LP) and Matlab 2014
(Mathworks, Inc) were used to perform the statistical analyses.
Results
A total of 1101 patients (male/female: 742/359, mean age: 67.3
years ± 11.2) were included in the registry. Six hundred and seventy-
nine retrospective and 422 prospective cases were collected. Most
of the cardioversions were elective (1050 cases), acute cardiover-
sions were done only 51 times, where acute procedure was defined
as a cardioversion performed on a haemodynamically unstable
patient. Nearly all cardioversions were electrical (97%), only 3%
were pharmacological. 405 patients were recorded in Hungary, 200
in Italy, 193 in Lithuania, 186 in Spain, and 116 in France.
Oral anticoagulants were administered in 87% of the patients. The
usage of NOACs vs. VKA was 31.5% vs. 68.5%, respectively. Thirteen
percent of the subjects were cardioverted without oral anticoagu-
lants, because of an AF duration of <48 h in most cases (83.3%).
OAC prescription habits were also documented. No differences
were found between NOACs and VKA in de novo prescriptions prior
to scheduled cardioversions (NOAC: 20% vs. VKA: 19%; P= 0.68).
Also we analysed previously anticoagulated and treatment-naive
patients, and there were no differences in the use of NOACs and
VKA between the groups (previously prescribed: 30.2% NOACs vs.
new treatment: 30.3% NOACs, P= 0.99).
Also there were no differences between the duration of OAC
before cardioversion, i.e. most of the patients received 3 or more
weeks of OAC in both the NOACs and the VKA groups (86% vs.
84%; P= 0.51). In 87% of the patients taking NOACs and in 84% of
those taking VKA, the anticoagulants were given for more than 4
weeks after the procedure (P= 0.14). When using VKA, international
normalized ratio (INR) at cardioversion was above 2.0 in 76% of the
cases.
When examining OAC strategies over time a decline in VKA usage
(P= 0.033) in elective cardioversion over approximately 1 year was
observed (Figure 1A). During the observation period an increase in
apixaban (P< 0.001), a slight increase in rivaroxaban (P= 0.028) and
no changes in dabigatran (P= 0.34) usage for elective cardioversion
was recorded (Figure 1B).























































There were differences in use of anticoagulants between the coun-
tries: Spain used most VKA (89%), while France used least VKA (39%,
P< 0.001). There were no large differences in VKA usage between
Italy, Hungary and Lithuania (Figure 2).
Discussion
According to large randomized prospective clinical studies, NOACs
were shown to be at least non-inferior to VKA in the prevention of
stroke in patients with AF.6–9 Further, NOACs have been shown to
be safe alternatives to VKA during cardioversion.13–16
To examine anticoagulation strategies in different European coun-
tries our research group created a cardioversion registry of 1101
patients enrolled over approximately 1 year. According to our results
only approximately 3/4 of the patients receiving VKA reached thera-
peutic INR levels during cardioversion, which is a concern given the
predominantly elective and iatrogenic nature of cardioversion and
the known increased risk for thromboembolism. On the other hand,
in our registry most patients received anticoagulation more than 3
weeks before and more than 4 weeks after cardioversion which is
similar to the results of the European Heart Rhythm Association
Survey.21 No differences were observed between the NOACs and
VKA groups in the duration of OAC. In the X-VERT13 trial a signifi-
cantly shorter time to cardioversion was observed in the rivaroxaban
group as opposed to the VKA group. According to the ENSURE-
AF14 trial there was no difference in time to cardioversion between
the edoxaban and warfarin group, which was explained by optimized
warfarin dosing and enoxaparin bridging therapy. In our study, the
exact duration from start of treatment to the cardioversion proce-
dure was not registered. However, the relatively low number of sub-
jects reaching therapeutic INRs may indirectly suggest that patients
underwent a longer treatment period in the VKA group, and hence a
reduced time to cardioversion in the NOAC group after the initial 3
weeks.
One of the conclusions of our registry is that despite several prac-
tical advantages of NOACs over VKAs, clinicians appear to hesitate
to embrace their usage during cardioversions. According to a
Norvegian registry in total 32 675 patients with AF 65.1% was given
NOACs, but in our cardioversion registry the usage of NOACs was
only 31.5%.22 One of the reasons may be that compliance (persis-
tence and adherence) is harder to monitor in NOACs than in VKAs,
which is of extreme importance when performing cardioversion.
The slight increase in rivaroxaban usage over time might well be a
reflection of the publication of the X-VERT trial in 2014, the first pro-
spective trial to show the safety and efficacy of a NOAC during cardi-
oversion when compared to warfarin. Dabigatran was the first choice
in most of the countries in the first 4 months of our observational
period, and it remained at a stable usage ratio. Apixaban was the least
prescribed NOAC during the first few months, but a substantial
increase throughout the observational period of one year was
recorded. In a Danish registry between 2011 and 2015, a decreasing
usage of VKA in general AF management was observed, and among
Figure 1 (A) Changes in OAC usage over time. (B) Changes in NOAC usage over approximately 1 year (enlarged portion of Figure 1A).

















Figure 2 VKA usage in different European countries.





















































































.NOACs a rise of apixaban and a decrease of dabigatran was
noticed.23 Similarly, an expanding use of NOACs was reported in the
GARFIELD-AF registry, and there were differences between coun-
tries similar to our results in the cardioversion population.24
Differences of NOAC usage between countries depend predomi-
nantly on regulatory as well as economic factors.
The design of this registry purposely focused on the use of oral
anticoagulants, however outcome data of stroke and systemic embo-
lism and safety endpoints such as bleeding events would be of great
additional value to this work. These will be subject for future
research and will receive highest priority.
Conclusions
Taken together, our study shows that most patients did receive oral
anticoagulants during cardioversion. VKAs were used more often (2/
3 vs. 1/3) than NOACs in this particular setting. However, our results
show a significant decrease in VKA usage over time, while NOAC
usage displays a gradual increase. As NOACs are more and more
widely used in AF in general, further studies in the cardioversion set-
ting will be needed to understand their optimal role in this aspect of
AF patient management.
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